Contact
searchSearch
HMP Global
Login

Lung Cancer

.st0 {fill: #000;}
Durvalumab Shows Promise in Phase 2 Trial of Patients With Pleural Mesothelioma
Videos
Durvalumab Shows Promise in Phase 2 Trial of Patients With Pleural Mesothelioma
06/30/2020
Claire Verschraegen, MD, comments on a phase 2 study examining the use of chemotherapy with durvalumab in patients with pleural mesothelioma.
Claire Verschraegen, MD, comments on a phase 2 study examining the use of chemotherapy with durvalumab in patients with pleural mesothelioma.
Claire Verschraegen, MD,...
06/30/2020
Oncology
.st0 {fill: #000;}
Researchers Demonstrate Promising Efficacy of Lorlatinib in Patients With ALK+ NSCLC
Videos
Researchers Demonstrate Promising Efficacy of Lorlatinib in Patients With ALK+ NSCLC
06/10/2020
David Carbone, MD, PhD, offers his perspective on 2 clinical trials that evaluated the use of lorlatinib in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, offers his perspective on 2 clinical trials that evaluated the use of lorlatinib in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, offers...
06/10/2020
Oncology
.st0 {fill: #000;}
Alectinib Extends Survival in Treatment-Naïve Patients With ALK+ NSCLC
Videos
Alectinib Extends Survival in Treatment-Naïve Patients With ALK+ NSCLC
06/04/2020
Yasir Elamin, MD, discusses the findings of a study comparing alectinib with crizotinib in treatment-naïve patients with ALK-positive NSCLC.
Yasir Elamin, MD, discusses the findings of a study comparing alectinib with crizotinib in treatment-naïve patients with ALK-positive NSCLC.
Yasir Elamin, MD, discusses the...
06/04/2020
Oncology
.st0 {fill: #000;}
Combining Immuno-Oncology and Standard Chemo in the Treatment of NSCLC
Videos
Combining Immuno-Oncology and Standard Chemo in the Treatment of NSCLC
06/03/2020
Solange Peters, MD, PhD, provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what the findings of these studies mean for the treatment of patients with NSCLC.
Solange Peters, MD, PhD, provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what the findings of these studies mean for the treatment of patients with NSCLC.
Solange Peters, MD, PhD,...
06/03/2020
Oncology
.st0 {fill: #000;}
NGS of Cell-Free Plasma DNA Shows Value in Management of Patients With ALK+ NSCLC
Videos
NGS of Cell-Free Plasma DNA Shows Value in Management of Patients With ALK+ NSCLC
06/02/2020
David Carbone, MD, PhD, talks about the usefulness of NGS for cell-free plasma DNA in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, talks about the usefulness of NGS for cell-free plasma DNA in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, talks...
06/02/2020
Oncology
.st0 {fill: #000;}
Recent Advancements in the Treatment of HER2+ NSCLC
Videos
Recent Advancements in the Treatment of HER2+ NSCLC
06/01/2020
Solange Peters, MD, PhD, discusses the DESTINY trial and recent advancements made in the exploration of treatment options for patients with HER2-positive NSCLC.
Solange Peters, MD, PhD, discusses the DESTINY trial and recent advancements made in the exploration of treatment options for patients with HER2-positive NSCLC.
Solange Peters, MD, PhD,...
06/01/2020
Oncology
.st0 {fill: #000;}
Videos
Anti–PD-L1 Therapy Not Recommended for Patients With NSCLC, Active Brain Metastases
06/01/2020
David Carbone, MD, PhD, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases.
David Carbone, MD, PhD, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases.
David Carbone, MD, PhD, comments...
06/01/2020
Oncology
.st0 {fill: #000;}
Lorlatinib Shows Promise in Real-World Study of Patients With ALK+ NSCLC
Videos
Lorlatinib Shows Promise in Real-World Study of Patients With ALK+ NSCLC
06/01/2020
Yasir Elamin, MD, talks about how a study examining the real-world use of lorlatinib for ALK-positive NSCLC supports previously reported phase 2 trial data about this drug.
Yasir Elamin, MD, talks about how a study examining the real-world use of lorlatinib for ALK-positive NSCLC supports previously reported phase 2 trial data about this drug.
Yasir Elamin, MD, talks about...
06/01/2020
Oncology
.st0 {fill: #000;}
News
LCT With Brigatinib Shows Efficacy in TKI-Naïve Patients With ALK-Positive NSCLC
05/31/2020
Study findings posit LCT with brigatinib as a safe and effective treatment option for patients with ALK-rearranged advanced NSCLC, regardless of the number of metastatic sites.
Study findings posit LCT with brigatinib as a safe and effective treatment option for patients with ALK-rearranged advanced NSCLC, regardless of the number of metastatic sites.
Study findings posit LCT with...
05/31/2020
Oncology
.st0 {fill: #000;}
Brigatinib Plus LCT Safe, Feasible for TKI-Naïve Patients With ALK+ NSCLC
Videos
Brigatinib Plus LCT Safe, Feasible for TKI-Naïve Patients With ALK+ NSCLC
05/31/2020
Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.
Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.
Yasir Elamin, MD, talks about...
05/31/2020
Oncology
.st0 {fill: #000;}
Experts Identify Mutational Biomarker for Poor Prognosis in ALK+ NSCLC
Videos
Experts Identify Mutational Biomarker for Poor Prognosis in ALK+ NSCLC
05/30/2020
David Carbone, MD, PhD, comments on a study in which a mutation was identified as a biomarker for poor prognosis in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, comments on a study in which a mutation was identified as a biomarker for poor prognosis in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, comments...
05/30/2020
Oncology
.st0 {fill: #000;}
Combining LCT and Brigatinib May Benefit Patients With ALK+ NSCLC
Videos
Combining LCT and Brigatinib May Benefit Patients With ALK+ NSCLC
05/27/2020
David Carbone, MD, PhD, comments on a study evaluating the use of LCT plus brigatinib for patients with ALK-positive NSCLC.
David Carbone, MD, PhD, comments on a study evaluating the use of LCT plus brigatinib for patients with ALK-positive NSCLC.
David Carbone, MD, PhD, comments...
05/27/2020
Oncology
.st0 {fill: #000;}
News
EZH2-Inhibitor Shows Activity in Relapsed/Refractory Malignant Mesothelioma
05/27/2020
Phase 2 trial data demonstrate the antitumor activity of tazemetostat in patients with BAP1-deficient relapsed or refractory malignant mesothelioma.
Phase 2 trial data demonstrate the antitumor activity of tazemetostat in patients with BAP1-deficient relapsed or refractory malignant mesothelioma.
Phase 2 trial data demonstrate...
05/27/2020
Oncology
.st0 {fill: #000;}
Pembrolizumab Added to Chemo Maintains OS, PFS Benefits in Metastatic NSCLC
Videos
Pembrolizumab Added to Chemo Maintains OS, PFS Benefits in Metastatic NSCLC
05/27/2020
Yasir Elamin, MD, discusses the clinical significance of the KEYNOTE-189 clinical trial evaluating the use of chemo plus pembrolizumab for metastatic, nonsquamous NSCLC.
Yasir Elamin, MD, discusses the clinical significance of the KEYNOTE-189 clinical trial evaluating the use of chemo plus pembrolizumab for metastatic, nonsquamous NSCLC.
Yasir Elamin, MD, discusses the...
05/27/2020
Oncology
.st0 {fill: #000;}
First-Line Pemetrexed Plus Carboplatin and Gefitinib a New Standard Option for EGFR-Positive NSCLC
06/03/2019
Findings presented at ASCO 2019 show that first-line pemetrexed plus carboplatin and gefitinib is a new standard treatment option for patients with EGFR-positive NSCLC.
Findings presented at ASCO 2019 show that first-line pemetrexed plus carboplatin and gefitinib is a new standard treatment option for patients with EGFR-positive NSCLC.
Findings presented at ASCO 2019...
06/03/2019
Oncology
.st0 {fill: #000;}
Neoadjuvant Atezolizumab Yields Encouraging Responses in Patients With Resectable NSCLC
06/01/2019
Interim data from a large study of patients with early-stage NSCLC being presented at ASCO 2019 show that neoadjuvant atezolizumab is well-tolerated, and yields encouraging responses.
Interim data from a large study of patients with early-stage NSCLC being presented at ASCO 2019 show that neoadjuvant atezolizumab is well-tolerated, and yields encouraging responses.
Interim data from a large study...
06/01/2019
Oncology
.st0 {fill: #000;}
Daily Metformin With Chemoradiotherapy Does Not Improve Survival in Locally Advanced NSCLC
06/01/2019
Study findings presented at ASCO 2019 show that daily metformin use combined with chemoradiotherapy for locally advanced NSCLC was well-tolerated but did not improve survival.
Study findings presented at ASCO 2019 show that daily metformin use combined with chemoradiotherapy for locally advanced NSCLC was well-tolerated but did not improve survival.
Study findings presented at ASCO...
06/01/2019
Oncology

About the ASCO Annual Meeting

Experts from across the globe gather to discover and share groundbreaking research among members of the cancer care community who diagnose, treat, and study patients with multiple types of cancer.

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use